AMRI, Metrion Biosciences team up to provide ion channel drug discovery services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/selvanegra)
(Image: Getty/selvanegra)

Related tags: Amri, Metrion Biosciences, Drug discovery, Contract research organisation, Contract research, Ion channel

The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.

The contract research, development, and manufacturing organization (CDMO) AMRI ​has aligned with Metrion Biosciences​, a specialist ion channel contract research organization (CRO) and drug discovery company.

Under the collaboration agreement, AMRI will offer its clients access to Metrion's portfolio of assay tools and technologies for ion channel screening, cardiac safety profiling, and neuroscience applications.

In turn, Metrion customers will gain access to AMRI's suite of integrated drug discovery solutions, which includes medicinal chemistry, high content imaging, cell-based assays, high-throughput screening and screening by mass spectrometry.

“Ion channels are a class of well-validated drug targets. Many ion channels are linked to human disease by known disease-causing mutations in human,”​ said Kathy Bove, VP of global drug discovery business development at AMRI.

Further, there are numerous approved drugs that target ion channels, several of which have reached blockbuster status, she explained.

“Novel findings linking ion channels to other diseases and new technology approaches to find drugs effecting ion channel function make this an exciting class of targets for future drug discovery,” ​Bove told us. 

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more